The company's technology is based on immune modulation and transplant research, led by Dr. Maria Siemionow, a renowned expert in microsurgery and transplantation. Tolera Therapeutics' therapies target the human alpha-beta T-cell receptor, rendering pathologic T-cells inert and expanding regulatory T-cells in a novel, non-depleting manner. This unique approach improves the lives of patients with autoimmune and immune-mediated diseases, reducing or eliminating the need for chronic immunosuppression therapies and their dangerous side effects.